Walvax Biotechnology Co Ltd (Walvax) is a biopharmaceutical company that develops, produces and markets bio-medical products including vaccines and blood products. The company's products include the Haemophilus influenza vaccine for the prevention of infectious diseases such as meningitis. Walvax offers drugs for pneumonia, septicemia, cellulitis, arthritis and epiglottitis. It offers Group A and C meningococcal polysaccharide vaccines for preventing diseases such as cerebrospinal meningitis and septicemia and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. The company markets its products through a distribution network in China. The company operates a research and development center in Kunming. Walvax is headquartered in Kunming, China.
Headquarters
China
Address
No. 395, Kexin Road, Kunming, Yunnan, 650101
Website
www.walvax.com
Telephone
86 871 68312779
No of Employees
2,388
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300142 (SHE)
Revenue (2022)
$581.6M
-19.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-42.4%
(2022 vs 2021)
Market Cap*
$3.1B
Net Profit Margin (2022)
XYZ
-28.9%
(2022 vs 2021)
* As of and is in US$
Walvax Biotechnology Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Bivalent Human Papillomavirus Vaccine (Pichia Pastoris) | Walvax |
| 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine | |
| 23-Valent Pneumococcal Polysaccharide Vaccine | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Walvax Biotechnology Co Ltd | Cachet Pharmaceutical Co Ltd | Hainan Haiyao Co Ltd | Beijing SL Pharmaceutical Co Ltd | BioStar Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Kunming | Beijing | Haikou | Beijing | Xianyang |
| State/Province | Yunnan | Beijing | Hainan | Beijing | Shaanxi |
| No. of Employees | 2,388 | 2,294 | 2,247 | 757 | 438 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Yunchun | Chairman | Executive Board | 2009 | 61 |
| Jiang Runsheng | Director; President | Executive Board | 2019 | 66 |
| Zhou Hua | Director - Finance | Senior Management | 2014 | 56 |
| Dong Shaozhong | Vice President; Director - Staff | Senior Management | 2022 | 55 |
| Zhang Jiankang | Vice President; Director - Staff | Senior Management | 2020 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer